Leishmune, the first prophylactic vaccine licensed against canine visceral leishmaniasis (CVL), has been used in Brazil since 2004, where seropositive dogs are sacrificed in order to control human visceral leishmaniasis (VL). We demonstrate here that vaccination with Leishmune does not interfere with the serological control campaign (110,000 dogs). Only 1.3% of positivity (76 among 5860) was detected among Leishmune uninfected vaccinees. We also analyzed the possible additive effect of Leishmune vaccination over dog culling, on the decrease of the incidence of CVL and VL in two Brazilian endemic areas, from 2004 to 2006. In Araçatuba, a 25% of decline was seen in CVL with a 61% decline in human cases, indicating the additive effect of Leishmune vaccination of 5.7% of the healthy dogs (1419 dogs), on regular dog culling. In Belo Horizonte (BH), rising curves of canine and human incidence were observed in the districts of Barreiro, Venda Nova and Noroeste, while the canine and human incidence of Centro Sul, Leste, Nordeste, Norte, Pampulha and Oeste, started to decrease or maintained a stabilized plateau after Leishmune vaccination. Among the districts showing a percent decrease of human incidence (-36.5%), Centro Sul and Pampulha showed the highest dog vaccination percents (63.27% and 27.27%, respectively) and the lowest dog incidence (-3.36% and 1.89%, respectively). They were followed by Oeste, that vaccinated 25.30% of the animals and experienced an increase of only 12.86% of dog incidence and by Leste and Nordeste, with lower proportions of vaccinees (11.72% and 10.76%, respectively) and probably because of that, slightly higher canine incidences (42.77% and 35.73%). The only exception was found in Norte district where the reduced human and canine incidence were not correlated to Leishmune vaccination. Much lower proportions of dogs were vaccinated in Venda Nova (4.35%), Noroeste (10.27%) and Barreiro (0.09%) districts, which according to that exhibited very increased canine incidences (24.48%, 21.85% and 328.57%, respectively), and pronounced increases in human incidence (14%, 4% and 17%, respectively). The decrease of canine (p=-0.008) and human incidences (p=-0.048) is directly correlated to the increase of the number of vaccinated dogs, confirming the additive control effect of Leishmune vaccination over dog culling, reducing the parasite reservoir, protecting dogs and, in this way, reducing the risk of transmission of VL to humans and becoming a new effective control tool.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2009.03.045DOI Listing

Publication Analysis

Top Keywords

leishmune vaccination
20
human incidence
16
visceral leishmaniasis
12
dog culling
12
human
9
leishmune
9
decrease incidence
8
canine
8
human canine
8
canine visceral
8

Similar Publications

Diagnosis of Canine Visceral Leishmaniasis by Flow Cytometry Serology using the rMELEISH Multiepitope Antigen Coupled in a Functional Bead.

Curr Pharm Biotechnol

September 2024

Laboratório de Doenças Infecto-parasitárias, Universidade Federal de São João Del-Rei, Divinópolis, MG, 35501- 296, Brazil.

Background: Visceral leishmaniasis (VL) is a zoonotic disease, with dogs being the main reservoir of the .

Objective: To develop a new flow cytometry test to diagnosis canine VL (CVL) diagnosis.

Methods: The current study addresses a new flow cytometry test using beads coupled to the multiepitope antigen rMELEISH.

View Article and Find Full Text PDF

Dogs are the main reservoir of in endemic regions. Canine leishmaniasis, caused by , can progress to a chronic disease resulting in death. Vaccines have been developed with a certain degree of success.

View Article and Find Full Text PDF

Phase I and II Clinical Trial Comparing the LBSap, Leishmune, and Leish-Tec Vaccines against Canine Visceral Leishmaniasis.

Vaccines (Basel)

November 2020

Laboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas/NUPEB, Universidade Federal de Ouro Preto, CEP 35400-000 Ouro Preto, Brazil.

In this study, we performed a phase I and II clinical trial in dogs to evaluate the toxicity and immunogenicity of LBSap-vaccine prototype, in comparison to Leishmune and Leish-Tec vaccines. Twenty-eight dogs were classified in four groups: (i) control group received 1 mL of sterile 0.9% saline solution; (ii) LBSap group received 600 μg of promastigotes protein and 1 mg of saponin adjuvant; (iii) Leishmune; and (iv) Leish-Tec.

View Article and Find Full Text PDF

Although viruses and bacteria have been known as agents of diseases since 1546, 250 years went by until the first vaccines against these pathogens were developed (1796 and 1800s). In contrast, Malaria, which is a protozoan-neglected disease, has been known since the 5th century BCE and, despite 2,500 years having passed since then, no human vaccine has yet been licensed for Malaria. Additionally, no modern human vaccine is currently licensed against Visceral or Cutaneous leishmaniasis.

View Article and Find Full Text PDF
Article Synopsis
  • Various prevention methods exist, including topical insecticides, immunotherapy, and four licensed vaccines developed since 2004 in Brazil and Europe.
  • Despite their availability, concerns persist about the vaccines' effectiveness and potential issues like affecting the accuracy of serological tests, indicating a need for ongoing research and monitoring in endemic regions.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!